{"filing":{"accession_number":"0001193125-26-274950","cik":"0001177648","ticker":"ENTA","company_name":"ENANTA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"d159604d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/d159604d8k.htm"},"events":[{"id":11694,"run_id":10277,"accession_number":"0001193125-26-274950","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Enanta announced advancement of zelicapavir into a registrational Phase 2b/3 clinical trial following a successful End-of-Phase 2 FDA meeting, plus initiation of a pediatric Phase 2b trial, both with topline data expected in 2027. This represents material clinical development progress for a lead program in a clinical-stage biotech company, but does not fit neatly into the standard 8-K event taxonomy (not an earnings release, executive change, M\u0026A, impairment, or other discrete event type). The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and is clearly material to investors assessing the company's pipeline advancement and near-term catalysts.","company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8348,"accession_number":"0001193125-26-274950","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Enanta announced advancement of zelicapavir into a registrational Phase 2b/3 clinical trial following a successful End-of-Phase 2 FDA meeting, plus initiation of a pediatric Phase 2b trial, both with topline data expected in 2027. This represents material clinical development progress for a lead program in a clinical-stage biotech company, but does not fit neatly into the standard 8-K event taxonomy (not an earnings release, executive change, M\u0026A, impairment, or other discrete event type). The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and is clearly material to investors assessing the company's pipeline advancement and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T11:14:08.198162+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8348,"accession_number":"0001193125-26-274950","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Enanta announced advancement of zelicapavir into a registrational Phase 2b/3 clinical trial following a successful End-of-Phase 2 FDA meeting, plus initiation of a pediatric Phase 2b trial, both with topline data expected in 2027. This represents material clinical development progress for a lead program in a clinical-stage biotech company, but does not fit neatly into the standard 8-K event taxonomy (not an earnings release, executive change, M\u0026A, impairment, or other discrete event type). The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and is clearly material to investors assessing the company's pipeline advancement and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T11:14:08.198162+00:00","company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","filing_date":"2026-06-18"}]}